AIRR - ANZCA Institutional Research Repository
Skip navigation
Please use this identifier to cite or link to this item: http://hdl.handle.net/11055/575
Title: Efficacy of flurbiprofen 8.75 mg spray in patients with sore throat due to an upper respiratory tract infection: A randomised controlled trial
Authors: de Looze, Ferdinandus
Russo, Marc
Bloch, Mark
Montgomery, Barney
Shephard, Adrian
Smith, Gary
Aspley,Sue
Anzca Brief Name: Russo, M
Keywords: flurbiprofen
non-steroidal anti-inflammatory
pharyngitis
respiratory tract infection
spray
sore throat
Issue Date: Jun-2016
Citation: 22(2):111-118
Abstract: BACKGROUND: Viral infections cause most cases of pharyngitis (sore throat); consequently, antibiotics are generally not warranted. However, a treatment targeting pain and inflammation, e.g. a topical non-steroidal anti-inflammatory spray, may be helpful for patients. OBJECTIVE: To evaluate the efficacy and safety of flurbiprofen 8.75 mg spray. METHODS: This randomised, double-blind, parallel group study was conducted at six community-based clinical research centres in Australia and two in New Zealand. Adults with sore throat due to upper respiratory tract infection (onset ≤ four days) took one dose of flurbiprofen (n = 249) or placebo spray (n = 256); after six hours, they could re-dose every three-six hours as required, for three days (max. five doses/day). The primary endpoint was the area under the change from baseline curve in throat soreness from zero-two hours (AUC0-2h). The change from baseline in other sore throat symptoms also assessed efficacy. RESULTS: The mean AUC0-2h for throat soreness was significantly greater with flurbiprofen spray (-1.82; 95% CI: -1.98 to 1.65) compared with placebo (-1.13; 95% CI: -1.27 to 0.99) (P < 0.0001). Significantly greater reductions from baseline were observed with flurbiprofen spray compared with placebo from the first time-points assessed (five minutes for throat soreness/difficulty swallowing, 20 minutes for sore throat pain intensity and 30 minutes for swollen throat) for up to six hours (P < 0.05 for all). There was no significant difference in adverse events between treatment groups during the three-day study. CONCLUSION: Flurbiprofen spray provides rapid and long-lasting relief from sore throat symptoms, and is well-tolerated over three days.
URI: http://hdl.handle.net/11055/575
DOI: 10.3109/13814788.2016.1145650
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/27028316
Study Name: ACTRN12612000457842
Journal Title: European Journal of General Practice
Type: Journal Article
Affiliates: AusTrials Pty Ltd, Sherwood, QLD, Australia and School of Medicine , University of Queensland , Brisbane , QLD , Australia
Hunter Clinical Research , Broadmeadow , Newcastle , NSW , Australia
Holdsworth House Medical Practice , Darlinghurst , NSW , Australia
Optimal Clinical Trials , Auckland , New Zealan
Reckitt Benckiser Healthcare International Ltd. , Slough , Berkshire , UK
Study/Trial: Randomized Controlled Clinical Trial/Controlled Clinical Trial
Appears in Collections:Scholarly and Clinical



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.